CIK: 0001534261
Total reported value
$1.3B
Reporting period: 2026-03-31 · Number of holdings: 40
Casdin Capital, LLC disclosed 40 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $1.3B and a quarterly turnover rate of 48.0%.
Browse other institutions with $1B to $10B AUMBrowse other institutions starting with "C"
Casdin Capital, LLC's disclosed holdings carry a Herfindahl concentration index of 0.090 — mathematically equivalent to about 11 equally-sized positions, well below its 40 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes vary widely across the portfolio (a coefficient of variation of 1.64), with a handful of outsized bets alongside many smaller positions.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Sector classification currently covers about 33% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Trim WGS
0.0% -$198.0M
Add RVMD
0.0% $45.4M
Add RLAY
+10.9% $33.5M
Add TXG
+62.5% $25.5M
Trim LAB
0.0% -$32.0M
Trim GPCR
0.0% -$25.1M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | RVMD | Revolution Medicines INC | Stock-Healthcare | 18.98% | +6.23% | — | |
| 2 | WGS | Genedx Holdings CORP | Stock-Other | 14.62% | -9.67% | — | |
| 3 | RLAY | Relay Therapeutics INC | Stock-Other | 10.86% | +4.03% | +10.88% | |
| 4 | BLFS | Biolife Solutions INC | Stock-Other | 8.61% | -0.34% | — | |
| 5 | LAB | Standard Biotools INC | Stock-Other | 6.18% | -0.88% | — | |
| 6 | ILMN | Illumina INC | Stock-Healthcare | 4.95% | +0.06% | -11.67% | |
| 7 | GPCR | Structure Therapeutics INC | Stock-Other | 4.29% | -0.79% | — | |
| 8 | TXG | 10x Genomics Inc-class A | Stock-Other | 3.66% | +2.24% | +62.50% | |
| 9 | DNLI | Denali Therapeutics INC | Stock-Other | 2.68% | +0.79% | — | |
| 10 | BEAM | Beam Therapeutics INC | Stock-Other | 2.44% | -0.31% | -15.63% | |
| 11 | GH | Guardant Health INC | Stock-Healthcare | 2.20% | -0.21% | -17.11% | |
| 12 | NGNE | Neurogene INC | Stock-Other | 2.17% | +0.51% | +9.65% | |
| 13 | ALNY | Alnylam Pharmaceuticals INC | Stock-Healthcare | 1.88% | +0.03% | — | |
| 14 | MAZE | Maze Therapeutics INC | Stock-Other | 1.72% | -0.23% | — | |
| 15 | SRRK | Scholar Rock Holding CORP | Stock-Other | 1.30% | +0.59% | +34.62% | |
| 16 | AGMB | Agomab Therapeutics NV | Stock-Other | 1.23% | +1.23% | NEW | |
| 17 | HIMS | Hims & Hers Health INC | Stock-Healthcare | 1.10% | +0.32% | +81.82% | |
| 18 | TSHA | Taysha Gene Therapies INC | Stock-Other | 1.10% | +0.59% | +116.67% | |
| 19 | QGEN | Qiagen N.V. | Stock-Healthcare | 1.09% | +1.09% | NEW | |
| 20 | TEM | Tempus Ai Inc-cl A | Stock-Healthcare | 1.01% | -0.07% | — | |
| 21 | SEPN | Septerna INC | Stock-Other | 1.01% | +0.05% | — | |
| 22 | GRAL | Grail INC | Stock-Healthcare | 0.90% | +0.90% | NEW | |
| 23 | PRME | Prime Medicine INC | Stock-Other | 0.83% | +0.15% | — | |
| 24 | PSNL | Personalis INC | Stock-Other | 0.77% | +0.77% | NEW | |
| 25 | DGX | Quest Diagnostics INC | Stock-Healthcare | 0.74% | +0.20% | — | |
| 26 | VCYT | Veracyte INC | Stock-Other | 0.67% | -0.05% | — | |
| 27 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.64% | +0.64% | NEW | |
| 28 | NTLA | Intellia Therapeutics INC | Stock-Other | 0.34% | +0.34% | NEW | |
| 29 | IRON | Disc Medicine INC | Stock-Other | 0.31% | +0.31% | NEW | |
| 30 | MRNA | Moderna INC | Stock-Healthcare | 0.29% | +0.29% | NEW | |
| 31 | ANL | Adlai Nortye Ltd-adr | Stock-Other | 0.28% | +0.28% | NEW | |
| 32 | GLUE | Monte Rosa Therapeutics INC | Stock-Other | 0.23% | +0.15% | +116.26% | |
| 33 | ABSI | Absci CORP | Stock-Other | 0.22% | +0.01% | — | |
| 34 | IPSC | Century Therapeutics INC | Stock-Other | 0.21% | +0.13% | — | |
| 35 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 0.19% | -0.03% | — | |
| 36 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 0.15% | +0.04% | — | |
| 37 | PACB | Pacific Biosciences Of Calif | Stock-Other | 0.07% | -0.42% | -82.86% | |
| 38 | RXRX | Recursion Pharmaceuticals-a | Stock-Healthcare | 0.04% | — | — | |
| 39 | TNYA | Tenaya Therapeutics INC | Stock-Other | 0.02% | — | — | |
| 40 | DNA | Ginkgo Bioworks Holdings INC | Stock-Other | 0.02% | — | — |
Performance for Q3 2026
+25.3%
Performance Last 4 Quarters
+51.2%
Based on 76% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 40 | $1.3B | 48 | |
| 2025-12-31 | 38 | $1.6B | 37 | |
| 2025-09-30 | 32 | $1.2B | 44 | |
| 2025-06-30 | 33 | $1.1B | 0 | |
| 2025-03-31 | 44 | $1.2B | 100 | |
| 2024-12-31 | 39 | $1.5B | 0 | |
| 2024-09-30 | 35 | $1.5B | 0 | |
| 2024-06-30 | 38 | $1.3B | 0 | |
| 2024-03-31 | 37 | $1.3B | 0 | |
| 2023-12-31 | 38 | $1.0B | 0 | |
| 2023-09-30 | 40 | $903.5M | 0 | |
| 2023-06-30 | 41 | $1.1B | 0 | |
| 2023-03-31 | 41 | $1.2B | 0 | |
| 2022-12-31 | 46 | $1.3B | 0 | |
| 2022-09-30 | 37 | $1.5B | 0 | |
| 2022-06-30 | 40 | $1.2B | 0 | |
| 2022-03-31 | 47 | $2.2B | 0 | |
| 2021-12-31 | 53 | $3.5B | 0 | |
| 2021-09-30 | 54 | $4.0B | 0 | |
| 2021-06-30 | 54 | $3.9B | 92 | |
| 2021-03-31 | 48 | $3.4B | 25 | |
| 2020-12-31 | 52 | $3.4B | 55 | |
| 2020-09-30 | 45 | $2.2B | 41 | |
| 2020-06-30 | 42 | $1.7B | 64 | |
| 2020-03-31 | 38 | $942.0M | 46 | |
| 2019-12-31 | 32 | $1.1B | 46 | |
| 2019-09-30 | 33 | $966.3M | 22 | |
| 2019-06-30 | 31 | $1.1B | 28 | |
| 2019-03-31 | 29 | $910.4M | 61 | |
| 2018-12-31 | 31 | $584.5M | 40 | |
| 2018-09-30 | 36 | $822.8M | 47 | |
| 2018-06-30 | 35 | $715.0M | 38 | |
| 2018-03-31 | 31 | $568.6M | 36 | |
| 2017-12-31 | 27 | $410.6M | 34 | |
| 2017-09-30 | 26 | $354.2M | 56 | |
| 2017-06-30 | 35 | $270.4M | 57 | |
| 2017-03-31 | 29 | $169.5M | 55 | |
| 2016-12-31 | 25 | $121.1M | 42 | |
| 2016-09-30 | 26 | $123.5M | 53 | |
| 2016-06-30 | 27 | $100.5M | 53 | |
| 2016-03-31 | 26 | $87.1M | 60 | |
| 2015-12-31 | 31 | $113.2M | 0 |
Casdin Capital, LLC's most significant position changes for 2026-03-31: Sold out: Avidity Biosciences INC (RNAGBP); Sold out: Ars Pharmaceuticals INC (SPRY); Sold out: Unitedhealth Group INC (UNH); New buy: Agomab Therapeutics NV (AGMB); New buy: Qiagen N.V. (QGEN).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | RVMD | Revolution Medicines INC | +6.2% | — | Unchanged |
| 2 | RLAY | Relay Therapeutics INC | +4% | +10.88% | Add |
| 3 | TXG | 10x Genomics Inc-class A | +2.2% | +62.50% | Add |
| 4 | DNLI | Denali Therapeutics INC | +0.8% | — | Unchanged |
| 5 | TSHA | Taysha Gene Therapies INC | +0.6% | +116.67% | Add |
| 6 | SRRK | Scholar Rock Holding CORP | +0.6% | +34.62% | Add |
| 7 | NGNE | Neurogene INC | +0.5% | +9.65% | Add |
| 8 | HIMS | Hims & Hers Health INC | +0.3% | +81.82% | Add |
| 9 | DGX | Quest Diagnostics INC | +0.2% | — | Unchanged |
| 10 | GLUE | Monte Rosa Therapeutics INC | +0.2% | +116.26% | Add |
| 11 | PRME | Prime Medicine INC | +0.2% | — | Unchanged |
| 12 | IPSC | Century Therapeutics INC | +0.1% | — | Unchanged |
| 13 | ILMN | Illumina INC | +0.1% | -11.67% | Trim |
| 14 | SEPN | Septerna INC | +0.1% | — | Unchanged |
| 15 | CTNM | Contineum Therapeutics Inc-a | 0% | — | Unchanged |
| 16 | ALNY | Alnylam Pharmaceuticals INC | 0% | — | Unchanged |
| 17 | ABSI | Absci CORP | 0% | — | Unchanged |
| 18 | RXRX | Recursion Pharmaceuticals-a | — | — | Unchanged |
| 19 | DNA | Ginkgo Bioworks Holdings INC | — | — | Unchanged |
| 20 | TNYA | Tenaya Therapeutics INC | — | — | Unchanged |
| 21 | BBOT | Bridgebio Oncology Therapeut | 0% | — | Unchanged |
| 22 | VCYT | Veracyte INC | -0.1% | — | Unchanged |
| 23 | TEM | Tempus Ai Inc-cl A | -0.1% | — | Unchanged |
| 24 | GH | Guardant Health INC | -0.2% | -17.11% | Trim |
| 25 | MAZE | Maze Therapeutics INC | -0.2% | — | Unchanged |
| 26 | BEAM | Beam Therapeutics INC | -0.3% | -15.63% | Trim |
| 27 | BLFS | Biolife Solutions INC | -0.3% | — | Unchanged |
| 28 | PACB | Pacific Biosciences Of Calif | -0.4% | -82.86% | Trim |
| 29 | GPCR | Structure Therapeutics INC | -0.8% | — | Unchanged |
| 30 | LAB | Standard Biotools INC | -0.9% | — | Unchanged |
| 31 | WGS | Genedx Holdings CORP | -9.7% | — | Unchanged |
| 32 | RNAGBP | Avidity Biosciences INC | — | EXIT | Sold out |
| 33 | SPRY | Ars Pharmaceuticals INC | — | EXIT | Sold out |
| 34 | UNH | Unitedhealth Group INC | — | EXIT | Sold out |
| 35 | AGMB | Agomab Therapeutics NV | — | NEW | New buy |
| 36 | QGEN | Qiagen N.V. | — | NEW | New buy |
| 37 | GRAL | Grail INC | — | NEW | New buy |
| 38 | DXCM | Dexcom INC | — | EXIT | Sold out |
| 39 | CI | THE Cigna Group | — | EXIT | Sold out |
| 40 | PSNL | Personalis INC | — | NEW | New buy |
| 41 | INCY | Incyte CORP | — | EXIT | Sold out |
| 42 | MLTX | Moonlake Immunotherapeutics | — | NEW | New buy |
| 43 | LEGN | Legend Biotech Corp-adr | — | EXIT | Sold out |
| 44 | NTLA | Intellia Therapeutics INC | — | NEW | New buy |
| 45 | IRON | Disc Medicine INC | — | NEW | New buy |
| 46 | MRNA | Moderna INC | — | NEW | New buy |
| 47 | ANL | Adlai Nortye Ltd-adr | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-14 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-10-18 | Amendment | View on EDGAR |
| 2024-06-30 | 2024-08-14 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-14 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-14 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-15 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-14 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-14 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-15 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-16 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-14 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-11-15 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-08-16 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-05-17 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-02-16 | 13F-HR | View on EDGAR |
| 2020-09-30 | 2020-11-16 | 13F-HR | View on EDGAR |
| 2020-06-30 | 2020-08-14 | 13F-HR | View on EDGAR |
| 2020-03-31 | 2020-05-15 | 13F-HR | View on EDGAR |
| 2019-12-31 | 2020-02-14 | 13F-HR | View on EDGAR |
| 2019-09-30 | 2020-01-03 | Amendment | View on EDGAR |
| 2019-09-30 | 2019-11-12 | 13F-HR | View on EDGAR |
| 2019-09-30 | 2019-11-12 | Amendment | View on EDGAR |
| 2019-06-30 | 2019-08-13 | 13F-HR | View on EDGAR |
| 2019-03-31 | 2019-05-15 | 13F-HR | View on EDGAR |
| 2018-12-31 | 2019-02-13 | 13F-HR | View on EDGAR |
| 2018-09-30 | 2018-11-14 | 13F-HR | View on EDGAR |
| 2018-06-30 | 2018-08-20 | Amendment | View on EDGAR |
| 2018-06-30 | 2018-08-14 | 13F-HR | View on EDGAR |
| 2018-03-31 | 2018-05-15 | 13F-HR | View on EDGAR |
| 2017-12-31 | 2018-02-14 | 13F-HR | View on EDGAR |
| 2017-09-30 | 2017-11-14 | 13F-HR | View on EDGAR |
| 2017-06-30 | 2017-08-14 | 13F-HR | View on EDGAR |
| 2017-03-31 | 2017-05-15 | 13F-HR | View on EDGAR |
| 2016-12-31 | 2017-02-14 | 13F-HR | View on EDGAR |
| 2016-09-30 | 2016-11-14 | 13F-HR | View on EDGAR |
| 2016-06-30 | 2016-08-15 | 13F-HR | View on EDGAR |
| 2016-03-31 | 2016-05-09 | 13F-HR | View on EDGAR |
| 2015-12-31 | 2016-02-08 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001906594
Total reported value
$1.3B
502 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001845785
Total reported value
$1.3B
376 stks
2026-03-31
AUM within 0.1% of this institution
CIK 0001559077
Total reported value
$1.3B
275 stks
2024-06-30
Stale — no recent filing
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0000909661
Total reported value
$17.5B
172 stks
2026-03-31
1 of the top 5 holdings overlap, including Revolution Medicines INC
CIK 0001012622
Total reported value
$167.9M
22 stks
2025-12-31
Stale — no recent filing
1 of the top 5 holdings overlap, including Genedx Holdings CORP
CIK 0001056807
Total reported value
$3.1B
41 stks
2026-03-31
1 of the top 5 holdings overlap, including Revolution Medicines INC